Education on strengthening FDA authority and the safety of personal care products, including H.R. 3619 (Toxic-Free Beauty Act), H.R. 3620 (Cosmetic Safety for Communities of Color and Professional Salon Workers Act), H.R. 3621 (Cosmetic Fragrance and Flavor Ingredient Right to Know Act), H.R. 3622 (Cosmetic Supply Chain Transparency Act), proposals to regulate PFAS in cosmetic products, including H.R. 6519 (No PFAS in Cosmetics Act), and implementation of the Modernization of Cosmetics Regulation Act of 2022. Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in Fiscal Year 2024. Proposals to reform the FDA's GRAS standard, reassess and ban food additives, and food packaging-related legislation, including H.R. 6105 (No Toxics in Food Packaging Act) and S.3387 (Ensuring Safe and Toxic-Free Foods Act).
Duration: February 4, 2008
to
present
General Issues: Chemicals/Chemical Industry , Consumer Issues/Safety/Protection , Environmental/Superfund , Health Issues
Spending: about $1,100,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: U.S. Senate, House of Representatives, Consumer Product Safety Commission (CPSC), Natl Institutes of Health (NIH), Environmental Protection Agency (EPA), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Executive Office of the President (EOP), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Health & Human Services - Dept of (HHS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, The Raben Group lobbied for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) , earning $10,000. The report was filed on April 18.
Original Filing: 301553681.xml
Lobbying Issues
Education on strengthening FDA authority and the safety of personal care products, including H.R. 3619 (Toxic-Free Beauty Act), H.R. 3620 (Cosmetic Safety for Communities of Color and Professional Salon Workers Act), H.R. 3621 (Cosmetic Fragrance and Flavor Ingredient Right to Know Act), H.R. 3622 (Cosmetic Supply Chain Transparency Act), proposals to regulate PFAS in cosmetic products, including H.R. 6519 (No PFAS in Cosmetics Act), and implementation of the Modernization of Cosmetics Regulation Act of 2022. Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in Fiscal Year 2024. Proposals to reform the FDA's GRAS standard, reassess and ban food additives, and food packaging-related legislation, including H.R. 6105 (No Toxics in Food Packaging Act) and S.3387 (Ensuring Safe and Toxic-Free Foods Act).
Agencies Lobbied
U.S. Senate
Type of Issue
Chemicals/Chemical Industry/Superfund
Lobbying Issues
Education on strengthening FDA authority and the safety of personal care products, including H.R. 3619 (Toxic-Free Beauty Act), H.R. 3620 (Cosmetic Safety for Communities of Color and Professional Salon Workers Act), H.R. 3621 (Cosmetic Fragrance and Flavor Ingredient Right to Know Act), H.R. 3622 (Cosmetic Supply Chain Transparency Act), proposals to regulate PFAS in cosmetic products, including H.R. 6519 (No PFAS in Cosmetics Act), and implementation of the Modernization of Cosmetics Regulation Act of 2022. Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in Fiscal Year 2024. Proposals to reform the FDA's GRAS standard, reassess and ban food additives, and food packaging-related legislation, including H.R. 6105 (No Toxics in Food Packaging Act) and S.3387 (Ensuring Safe and Toxic-Free Foods Act).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
4th Quarter, 2023
In Q4, The Raben Group lobbied for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) , earning $10,000. The report was filed on Jan. 18.
Original Filing: 301528763.xml
Lobbying Issues
Education on strengthening FDA authority and the safety of personal care products, including H.R. 3619 (Toxic-Free Beauty Act), H.R. 3620 (Cosmetic Safety for Communities of Color and Professional Salon Workers Act), H.R. 3621 (Cosmetic Fragrance and Flavor Ingredient Right to Know Act), H.R. 3622 (Cosmetic Supply Chain Transparency Act), proposals to regulate PFAS in cosmetic products, including H.R. 6519 (No PFAS in Cosmetics Act), and implementation of the Modernization of Cosmetics Regulation Act of 2022. Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in Fiscal Year 2024. Proposals to reform the FDA's GRAS standard, reassess and ban food additives, and food packaging-related legislation, including H.R. 6105 (No Toxics in Food Packaging Act) and S.3387 (Ensuring Safe and Toxic-Free Foods Act).
Agencies Lobbied
U.S. Senate
Type of Issue
Chemicals/Chemical Industry/Superfund
Lobbying Issues
Education on strengthening FDA authority and the safety of personal care products, including H.R. 3619 (Toxic-Free Beauty Act), H.R. 3620 (Cosmetic Safety for Communities of Color and Professional Salon Workers Act), H.R. 3621 (Cosmetic Fragrance and Flavor Ingredient Right to Know Act), H.R. 3622 (Cosmetic Supply Chain Transparency Act), proposals to regulate PFAS in cosmetic products, including H.R. 6519 (No PFAS in Cosmetics Act), and implementation of the Modernization of Cosmetics Regulation Act of 2022. Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in Fiscal Year 2024. Proposals to reform the FDA's GRAS standard, reassess and ban food additives, and food packaging-related legislation, including H.R. 6105 (No Toxics in Food Packaging Act) and S.3387 (Ensuring Safe and Toxic-Free Foods Act).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
3rd Quarter, 2023
In Q3, The Raben Group lobbied for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) , earning $10,000. The report was filed on Oct. 18, 2023.
Original Filing: 301505173.xml
Lobbying Issues
Education on strengthening FDA authority and the safety of personal care products, including H.R. 3619 (Toxic-Free Beauty Act), H.R. 3620 (Cosmetic Safety for Communities of Color and Professional Salon Workers Act), H.R. 3621 (Cosmetic Fragrance and Flavor Ingredient Right to Know Act), H.R. 3622 (Cosmetic Supply Chain Transparency Act), proposals to regulate PFAS in cosmetic products, and implementation of the Modernization of Cosmetics Regulation Act of 2022. Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in Fiscal Year 2024. Proposals to reform the FDA's GRAS standard, reassess and ban food additives, and food packaging-related legislation.
Agencies Lobbied
U.S. Senate
Type of Issue
Chemicals/Chemical Industry/Superfund
Lobbying Issues
Education on strengthening FDA authority and the safety of personal care products, including H.R. 3619 (Toxic-Free Beauty Act), H.R. 3620 (Cosmetic Safety for Communities of Color and Professional Salon Workers Act), H.R. 3621 (Cosmetic Fragrance and Flavor Ingredient Right to Know Act), H.R. 3622 (Cosmetic Supply Chain Transparency Act), proposals to regulate PFAS in cosmetic products, and implementation of the Modernization of Cosmetics Regulation Act of 2022. Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in Fiscal Year 2024. Proposals to reform the FDA's GRAS standard, reassess and ban food additives, and food packaging-related legislation.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
2nd Quarter, 2023
In Q2, The Raben Group lobbied for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) , earning $10,000. The report was filed on July 20, 2023.
Original Filing: 301487534.xml
Lobbying Issues
Education on strengthening FDA authority and the safety of personal care products, including H.R. 3619 (Toxic-Free Beauty Act), H.R. 3620 (Cosmetic Safety for Communities of Color and Professional Salon Workers Act), H.R. 3621 (Cosmetic Fragrance and Flavor Ingredient Right to Know Act), H.R. 3622 (Cosmetic Supply Chain Transparency Act), proposals to regulate PFAS in cosmetic products, and implementation of the Modernization of Cosmetics Regulation Act of 2022. Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in Fiscal Year 2024. Proposals to reform the FDA's GRAS standard, reassess and ban food additives, and food packaging-related legislation.
Agencies Lobbied
U.S. Senate
Type of Issue
Chemicals/Chemical Industry/Superfund
Lobbying Issues
Education on strengthening FDA authority and the safety of personal care products, including H.R. 3619 (Toxic-Free Beauty Act), H.R. 3620 (Cosmetic Safety for Communities of Color and Professional Salon Workers Act), H.R. 3621 (Cosmetic Fragrance and Flavor Ingredient Right to Know Act), H.R. 3622 (Cosmetic Supply Chain Transparency Act), proposals to regulate PFAS in cosmetic products, and implementation of the Modernization of Cosmetics Regulation Act of 2022. Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in Fiscal Year 2024. Proposals to reform the FDA's GRAS standard, reassess and ban food additives, and food packaging-related legislation.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
1st Quarter, 2023
The Raben Group amended a lobbying report for representation of Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) in Q12023 on Nov. 6, 2023.
Original Filing: 301518435.xml
Lobbying Issues
Education on strengthening FDA authority and the safety of personal care products. Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in Fiscal Year 2024. Proposals to reform the FDA's GRAS standard and food packaging-related legislation.
Agencies Lobbied
U.S. Senate
Type of Issue
Chemicals/Chemical Industry/Superfund
Lobbying Issues
Education on strengthening FDA authority and the safety of personal care products. Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in Fiscal Year 2024. Proposals to reform the FDA's GRAS standard and food packaging-related legislation.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
1st Quarter, 2023
In Q1, The Raben Group lobbied for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) , earning $10,000. The report was filed on April 18, 2023.
Original Filing: 301455137.xml
Lobbying Issues
Education on strengthening FDA authority and the safety of personal care products. Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in Fiscal Year 2024. Proposals to reform the FDA's GRAS standard and food packaging-related legislation.
Agencies Lobbied
U.S. Senate
Type of Issue
Chemicals/Chemical Industry/Superfund
Lobbying Issues
Education on strengthening FDA authority and the safety of personal care products. Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in Fiscal Year 2024. Proposals to reform the FDA's GRAS standard and food packaging-related legislation.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
4th Quarter, 2022
In Q4, The Raben Group lobbied for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) , earning $10,000. The report was filed on Jan. 18, 2023.
Original Filing: 301430462.xml
Lobbying Issues
Proposals to reform FDA authority and personal care products regulatory system.
Specific bills include the Consolidated Appropriations Act, 2023 (H.R.2617), the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348).
Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill.
Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).
Agencies Lobbied
U.S. Senate
Type of Issue
Chemicals/Chemical Industry/Superfund
Lobbying Issues
Proposals to reform FDA authority and personal care products regulatory system.
Specific bills include the Consolidated Appropriations Act, 2023 (H.R.2617), the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348).
Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill.
Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
3rd Quarter, 2022
In Q3, The Raben Group lobbied for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) , earning $10,000. The report was filed on Oct. 19, 2022.
Original Filing: 301412141.xml
Lobbying Issues
Proposals to reform FDA authority and personal care products regulatory system.
Specific bills include the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348).
Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill.
Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).
Agencies Lobbied
U.S. Senate
Type of Issue
Chemicals/Chemical Industry/Superfund
Lobbying Issues
Proposals to reform FDA authority and personal care products regulatory system.
Specific bills include the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348).
Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill.
Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
2nd Quarter, 2022
In Q2, The Raben Group lobbied for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) , earning $10,000. The report was filed on July 19, 2022.
Original Filing: 301385142.xml
Lobbying Issues
Proposals to reform FDA authority and personal care products regulatory system.
Specific bills include the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348).
Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill.
Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).
Agencies Lobbied
U.S. Senate
Type of Issue
Chemicals/Chemical Industry/Superfund
Lobbying Issues
Proposals to reform FDA authority and personal care products regulatory system.
Specific bills include the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872), the FDA Safety and Landmark Achievements Act of 2022 (S.4348).
Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill.
Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
1st Quarter, 2022
In Q1, The Raben Group lobbied for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) , earning $10,000. The report was filed on April 18, 2022.
Original Filing: 301359795.xml
Lobbying Issues
Proposals to reform FDA authority and personal care products regulatory system.
Specific bills include the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872).
Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill.
Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).
Agencies Lobbied
U.S. Senate
Type of Issue
Chemicals/Chemical Industry/Superfund
Lobbying Issues
Proposals to reform FDA authority and personal care products regulatory system.
Specific bills include the Toxic Free Beauty Act (H.R. 5537), Cosmetic Fragrance and Flavor Ingredient Right to Know Act (H.R. 5538), Cosmetic Safety for Communities of Color and Professional Salon Workers Act (H.R. 5540), Cosmetic Supply Chain Transparency Act (H.R. 5539), No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act (H.R. 5872).
Funding for Centers for Disease Control Biomonitoring program and National Health Tracking Network in FY 2022 and FY 2023 Labor-HHS-Education bill.
Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), Keep Food Containers Safe from PFAS Act (H.R. 6026/S.3169), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
4th Quarter, 2021
In Q4, The Raben Group lobbied for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) , earning $10,000. The report was filed on Jan. 19, 2022.
Original Filing: 301328971.xml
Lobbying Issues
Proposals to reform FDA authority and personal care products regulatory system. Legislation that would strengthen supply chain transparency and safety of raw ingredients in cosmetics; ban toxic ingredients linked to harmful impacts on health; full fragrance and flavor ingredient disclosure; and health protections, including a ban on chemicals of concern in products marketed to women of color. Specific bills include the No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act.
Funding for Centers for Disease and Control Biomonitoring program and National Health Tracking Network in FY 22 Labor-HHS-Education bill.
Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), the Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).
Agencies Lobbied
U.S. Senate
Type of Issue
Chemicals/Chemical Industry/Superfund
Lobbying Issues
Proposals to reform FDA authority and personal care products regulatory system. Legislation that would strengthen supply chain transparency and safety of raw ingredients in cosmetics; ban toxic ingredients linked to harmful impacts on health; full fragrance and flavor ingredient disclosure; and health protections, including a ban on chemicals of concern in products marketed to women of color. Specific bills include the No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act.
Funding for Centers for Disease and Control Biomonitoring program and National Health Tracking Network in FY 22 Labor-HHS-Education bill.
Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), the Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
3rd Quarter, 2021
In Q3, The Raben Group lobbied for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) , earning $10,000. The report was filed on Oct. 19, 2021.
Original Filing: 301303396.xml
Lobbying Issues
Proposals to reform FDA authority and personal care products regulatory system. Legislation that would strengthen supply chain transparency and safety of raw ingredients in cosmetics; ban toxic ingredients linked to harmful impacts on health; full fragrance and flavor ingredient disclosure; and health protections, including a ban on chemicals of concern in products marketed to women of color. Specific bills include the No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act.
Funding for Centers for Disease and Control Biomonitoring program and National Health Tracking Network in FY 22 Labor-HHS-Education bill.
Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), the Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).
Agencies Lobbied
U.S. Senate
Type of Issue
Chemicals/Chemical Industry/Superfund
Lobbying Issues
Proposals to reform FDA authority and personal care products regulatory system. Legislation that would strengthen supply chain transparency and safety of raw ingredients in cosmetics; ban toxic ingredients linked to harmful impacts on health; full fragrance and flavor ingredient disclosure; and health protections, including a ban on chemicals of concern in products marketed to women of color. Specific bills include the No PFAS in Cosmetics Act (H.R. 3990/S.2047), Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act (S.2100); Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act.
Funding for Centers for Disease and Control Biomonitoring program and National Health Tracking Network in FY 22 Labor-HHS-Education bill.
Proposals to reform the FDA's GRAS standard and food-packaging related legislation, including the Toxic Free Food Act (H.R. 3699), the Preventing Harmful Exposure to Phthalates Act (H.R. 4963/S.2669), and the Food Chemical Reassessment Act of 2021 (H.R. 4694).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
2nd Quarter, 2021
In Q2, The Raben Group lobbied for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) , earning $10,000. The report was filed on July 19, 2021.
Original Filing: 301279930.xml
Lobbying Issues
Proposals to reform FDA authority and personal care products regulatory system. Legislation that would strengthen supply chain transparency and safety of raw ingredients in cosmetics; ban toxic ingredients linked to harmful impacts on health; full fragrance and flavor ingredient disclosure; and health protections, including a ban on chemicals of concern in products marketed to women of color. Specific bills include the Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act; Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act.
Funding for Centers for Disease and Control Biomonitoring program and National Health Tracking Network in FY 22 Labor-HHS-Education bill.
Agencies Lobbied
U.S. Senate
Type of Issue
Chemicals/Chemical Industry/Superfund
Lobbying Issues
Proposals to reform FDA authority and personal care products regulatory system. Legislation that would strengthen supply chain transparency and safety of raw ingredients in cosmetics; ban toxic ingredients linked to harmful impacts on health; full fragrance and flavor ingredient disclosure; and health protections, including a ban on chemicals of concern in products marketed to women of color. Specific bills include the Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act; Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act.
Funding for Centers for Disease and Control Biomonitoring program and National Health Tracking Network in FY 22 Labor-HHS-Education bill.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
1st Quarter, 2021
In Q1, The Raben Group lobbied for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) , earning $10,000. The report was filed on April 19, 2021.
Original Filing: 301259221.xml
Lobbying Issues
Proposals to reform FDA authority and personal care products regulatory system. Legislation that would strengthen supply chain transparency and safety of raw ingredients in cosmetics; ban toxic ingredients linked to harmful impacts on health; full fragrance and flavor ingredient disclosure; and health protections, including a ban on chemicals of concern in products marketed to women of color. Specific bills include the Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act; Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act.
Funding for Centers for Disease and Control Biomonitoring program and National Health Tracking Network in FY 22 Labor-HHS-Education bill.
Agencies Lobbied
U.S. Senate
Type of Issue
Chemicals/Chemical Industry/Superfund
Lobbying Issues
Proposals to reform FDA authority and personal care products regulatory system. Legislation that would strengthen supply chain transparency and safety of raw ingredients in cosmetics; ban toxic ingredients linked to harmful impacts on health; full fragrance and flavor ingredient disclosure; and health protections, including a ban on chemicals of concern in products marketed to women of color. Specific bills include the Safe Cosmetics and Personal Care Products Act, Personal Care Products Safety Act; Cosmetic Safety Enhancement Act; and the Natural Cosmetics Act.
Funding for Centers for Disease and Control Biomonitoring program and National Health Tracking Network in FY 22 Labor-HHS-Education bill.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
4th Quarter, 2020
In Q4, The Raben Group lobbied for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) , earning $10,000. The report was filed on Jan. 20, 2021.
Original Filing: 301239307.xml
Lobbying Issues
Proposals to reform FDA authority and personal care products regulatory system. Specifically, H.R. 4296 - Safe Cosmetics and Personal Care Products Act; S.726 - Personal Care Products Safety Act; H.R. 5279 - Cosmetic Safety Enhancement Act; and H.R. 5017 - Natural Cosmetics Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Chemicals/Chemical Industry/Superfund
Lobbying Issues
Proposals to reform FDA authority and personal care products regulatory system. Specifically, H.R. 4296 - Safe Cosmetics and Personal Care Products Act; S.726 - Personal Care Products Safety Act; H.R. 5279 - Cosmetic Safety Enhancement Act; and H.R. 5017 - Natural Cosmetics Act.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Consumer Issues/Safety/Protection
3rd Quarter, 2020
In Q3, The Raben Group did no lobbying for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) . The report was filed on Oct. 19, 2020.
Original Filing: 301216147.xml
2nd Quarter, 2020
In Q2, The Raben Group lobbied for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) . The report was filed on July 19, 2020.
Original Filing: 301194128.xml
Lobbying Issues
HOUSE AND SENATE APPROPRIATIONS
Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
CURRENT LEGISLATIVE PROPOSALS:
Breast Cancer Prevention Partners supports reforming and strengthening the personal care products regulatory system and is working to ensure strong, health-protective measures are included in any proposed legislation. This includes H.R. 4296 - Safe Cosmetics and Personal Care Products Act; S.726 - Personal Care Products Safety Act; H.R. 5279 - Cosmetic Safety Enhancement Act; H.R. 5017 - Natural Cosmetics Act; and additional proposals that would impact the regulation of cosmetics and personal care products.
Breast Cancer Prevention Partners visits Congressional offices to oppose H.R. 6044 - Accurate Labels Act, and other legislative proposals that seek to undermine transparency for consumers and undermine states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer products.
Breast Cancer Prevention Partners supports efforts to reintroduce legislation that establishes environmental justice as a consideration in the regulation of
pesticides and personal care products. These include H.R. 5986 - Environmental Justice for All Act and S.2236 - Environmental Justice Act of 2019.
FUTURE LEGISLATIVE PROPOSALS:
Breast Cancer Prevention Partners supports efforts to reintroduce legislation that would ban food containers composed, in whole or in part, of bisphenol A
(BPA).
Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their
health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
Breast Cancer Prevention Partners supports efforts to increase federal funding for research and to regulate per- and polyfluoroalkyl substances (PFAS).
Breast Cancer Prevention Partners supports legislation that would strengthen public health restrictions and set new standards on ethylene oxide emissions.
Breast Cancer Prevention Partners supports legislation that increases transparency and addresses personal care products labeled or packaged as "natural".
REGULATION AND LEGISLATIVE INTENT:
P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act - The Breast Cancer Prevention Partners is working to support and
encourage strong, health-protective implementation of the reforms enacted in the Toxic Substances Control Act (TSCA).
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Chemical Industry/Safety/Protection/Superfund
1st Quarter, 2020
In Q1, The Raben Group lobbied for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) , earning $10,000. The report was filed on April 17, 2020.
Original Filing: 301170991.xml
Lobbying Issues
HOUSE AND SENATE APPROPRIATIONS
Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
CURRENT LEGISLATIVE PROPOSALS:
Breast Cancer Prevention Partners supports reforming and strengthening the personal care products regulatory system and is working to ensure strong, health-protective measures are included in any proposed legislation. This includes H.R. 4296 - Safe Cosmetics and Personal Care Products Act; S.726 - Personal Care Products Safety Act; H.R. 5279 - Cosmetic Safety Enhancement Act; H.R. 5017 - Natural Cosmetics Act; and additional proposals that would impact the regulation of cosmetics and personal care products.
Breast Cancer Prevention Partners visits Congressional offices to oppose H.R. 6044 - Accurate Labels Act, and other legislative proposals that seek to undermine transparency for consumers and undermine states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer products.
Breast Cancer Prevention Partners supports efforts to reintroduce legislation that establishes environmental justice as a consideration in the regulation of
pesticides and personal care products. These include H.R. 5986 - Environmental Justice for All Act and S.2236 - Environmental Justice Act of 2019.
FUTURE LEGISLATIVE PROPOSALS:
Breast Cancer Prevention Partners supports efforts to reintroduce legislation that would ban food containers composed, in whole or in part, of bisphenol A
(BPA).
Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their
health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
Breast Cancer Prevention Partners supports efforts to increase federal funding for research and to regulate per- and polyfluoroalkyl substances (PFAS).
Breast Cancer Prevention Partners supports legislation that would strengthen public health restrictions and set new standards on ethylene oxide emissions.
Breast Cancer Prevention Partners supports legislation that increases transparency and addresses personal care products labeled or packaged as "natural".
REGULATION AND LEGISLATIVE INTENT:
P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act - The Breast Cancer Prevention Partners is working to support and
encourage strong, health-protective implementation of the reforms enacted in the Toxic Substances Control Act (TSCA).
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Chemical Industry/Safety/Protection/Superfund
4th Quarter, 2019
In Q4, The Raben Group lobbied for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) , earning $10,000. The report was filed on Jan. 20, 2020.
Original Filing: 301122189.xml
Lobbying Issues
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
CURRENT LEGISLATIVE PROPOSALS:
Breast Cancer Prevention Partners supports reform and strengthening of the personal care products regulatory system and is working to ensure strong, health-protective measures are included in any proposed legislation. This includes H.R. 4296, the Safe Cosmetics and Personal Care Products Act of 2019, S.726, the Personal Care Products Safety Act, and any other legislation that would impact the regulation of personal care products.
FUTURE LEGISLATIVE PROPOSALS:
Breast Cancer Prevention Partners visits Congressional offices to oppose legislative proposals that undermine transparency for consumers and undermine
states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer products.
Breast Cancer Prevention Partners supports efforts to reintroduce legislation that establishes environmental justice as a consideration in the regulation of
pesticides and personal care products.
Breast Cancer Prevention Partners supports efforts to reintroduce legislation that would ban food containers composed, in whole or in part, of bisphenol A
(BPA).
Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their
health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
Breast Cancer Prevention Partners supports efforts to increase federal funding for research and to regulate per- and polyfluoroalkyl substances (PFAS).
Breast Cancer Prevention Partners supports legislation that would strengthen public health restrictions and set new standards on ethylene oxide emissions.
Breast Cancer Prevention Partners supports legislation that increases transparency and addresses personal care products labeled or packaged as "natural".
REGULATION AND LEGISLATIVE INTENT:
P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act - The Breast Cancer Prevention Partners is working to support and
encourage strong, health-protective implementation of the reforms enacted in the Toxic Substances Control Act (TSCA).
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Chemical Industry/Safety/Protection/Superfund
3rd Quarter, 2019
In Q3, The Raben Group lobbied for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) , earning $10,000. The report was filed on Oct. 18, 2019.
Original Filing: 301069734.xml
Lobbying Issues
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
CURRENT LEGISLATIVE PROPOSALS:
Breast Cancer Prevention Partners supports reform and strengthening of the personal care products regulatory system and is working to ensure strong, health-protective measures are included in any proposed legislation. This includes H.R. 4296, the Safe Cosmetics and Personal Care Products Act of 2019, S.726, the Personal Care Products Safety Act, and any other legislation that would impact the regulation of personal care products.
FUTURE LEGISLATIVE PROPOSALS:
Breast Cancer Prevention Partners visits Congressional offices to oppose legislative proposals that undermine transparency for consumers and undermine
states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer products.
Breast Cancer Prevention Partners supports efforts to reintroduce legislation that establishes environmental justice as a consideration in the regulation of
pesticides and personal care products.
Breast Cancer Prevention Partners supports efforts to reintroduce legislation that would ban food containers composed, in whole or in part, of bisphenol A
(BPA).
Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their
health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
Breast Cancer Prevention Partners supports efforts to increase federal funding for research and to regulate per- and polyfluoroalkyl substances (PFAS).
Breast Cancer Prevention Partners supports legislation that would strengthen public health restrictions and set new standards on ethylene oxide emissions.
Breast Cancer Prevention Partners supports legislation that increases transparency and addresses personal care products labeled or packaged as "natural".
REGULATION AND LEGISLATIVE INTENT:
P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act - The Breast Cancer Prevention Partners is working to support and
encourage strong, health-protective implementation of the reforms enacted in the Toxic Substances Control Act (TSCA).
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Chemical Industry/Safety/Protection/Superfund
2nd Quarter, 2019
In Q2, The Raben Group lobbied for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) , earning $10,000. The report was filed on July 19, 2019.
Original Filing: 301051711.xml
Lobbying Issues
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
CURRENT LEGISLATIVE PROPOSALS:
Breast Cancer Prevention Partners supports reform and strengthening of the personal care products regulatory system and is working to ensure strong,
health-protective measures are included in any proposed legislation. This includes S.726, the Personal Care Products Safety Act, and any other legislation
that would impact the regulation of personal care products.
FUTURE LEGISLATIVE PROPOSALS:
Breast Cancer Prevention Partners visits Congressional offices to oppose legislative proposals that undermine transparency for consumers and undermine
states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer products.
Breast Cancer Prevention Partners supports efforts to reintroduce legislation that establishes environmental justice as a consideration in the regulation of
pesticides and personal care products.
Breast Cancer Prevention Partners supports efforts to reintroduce legislation that would ban food containers composed, in whole or in part, of bisphenol A
(BPA).
Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their
health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
Breast Cancer Prevention Partners supports efforts to increase federal funding for research and to regulate per- and polyfluoroalkyl substances (PFAS).
Breast Cancer Prevention Partners supports legislation that would strengthen public health restrictions and set new standards on ethylene oxide emissions.
REGULATION AND LEGISLATIVE INTENT:
P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act - The Breast Cancer Prevention Partners is working to support and
encourage strong, health-protective implementation of the reforms enacted in the Toxic Substances Control Act (TSCA).
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Chemical Industry/Safety/Protection/Superfund
1st Quarter, 2019
In Q1, The Raben Group lobbied for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) , earning $10,000. The report was filed on April 19, 2019.
Original Filing: 301032162.xml
Lobbying Issues
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
CURRENT LEGISLATIVE PROPOSALS:
Breast Cancer Prevention Partners supports reform and strengthening of the personal care products regulatory system and is working to ensure strong, health-protective measures are included in any proposed legislation. This includes S.726, the Personal Care Products Safety Act, and any other legislation that would impact the regulation of personal care products.
FUTURE LEGISLATIVE PROPOSALS:
Breast Cancer Prevention Partners visits Congressional offices to oppose legislative proposals that undermine transparency for consumers and undermine states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer products.
Breast Cancer Prevention Partners supports efforts to reintroduce legislation that establishes environmental justice as a consideration in the regulation of pesticides and personal care products.
Breast Cancer Prevention Partners supports efforts to reintroduce legislation that would ban food containers composed, in whole or in part, of bisphenol A (BPA).
Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
REGULATION AND LEGISLATIVE INTENT:
P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act - The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the reforms enacted in the Toxic Substances Control Act (TSCA).
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Chemical Industry/Safety/Protection/Superfund
4th Quarter, 2018
In Q4, The Raben Group lobbied for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) , earning $10,000. The report was filed on Jan. 18, 2019.
Original Filing: 301010126.xml
Lobbying Issues
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA.
CURRENT LEGISLATIVE PROPOSALS:
The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products.
The Breast Cancer Prevention Partners supports reform and strengthening of the personal care products regulatory system, and is working to ensure strong, health protective measures are included in legislation such as S.1113, the Personal Care Products Safety Act, and any other legislation that would impact the safety of personal care products including H.R. 6903, the Safe Cosmetics and Personal Care Products Act of 2018.
Breast Cancer Prevention Partners opposes the Accurate Labels Act (S.3019, H.R.6022) because it undermines transparency for consumers and undermines states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer goods.
FUTURE LEGISLATIVE PROPOSALS:
The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS).
REGULATION AND LEGISLATIVE INTENT:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Chemical Industry/Safety/Protection/Superfund
3rd Quarter, 2018
In Q3, The Raben Group lobbied for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) , earning $10,000. The report was filed on Oct. 19, 2018.
Original Filing: 300990779.xml
Lobbying Issues
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA.
CURRENT LEGISLATIVE PROPOSALS:
The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products.
The Breast Cancer Prevention Partners supports reform and strengthening of the personal care products regulatory system, and is working to ensure strong, health protective measures are included in legislation such as S.1113, the Personal Care Products Safety Act, and any other legislation that would impact the safety of personal care products including H.R. 6903, the Safe Cosmetics and Personal Care Products Act of 2018.
Breast Cancer Prevention Partners opposes the Accurate Labels Act (S.3019, H.R.6022) because it undermines transparency for consumers and undermines states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer goods.
FUTURE LEGISLATIVE PROPOSALS:
The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS).
REGULATION AND LEGISLATIVE INTENT:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Chemical Industry/Safety/Protection/Superfund
2nd Quarter, 2018
In Q2, The Raben Group lobbied for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) , earning $10,000. The report was filed on July 19, 2018.
Original Filing: 300970181.xml
Lobbying Issues
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA.
CURRENT LEGISLATIVE PROPOSALS:
The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products.
The Breast Cancer Prevention Partners supports reform and strengthening of the personal care products regulatory system, and is working to ensure strong, health protective measures are included in legislation such as S.1113, the Personal Care Products Safety Act, and any other legislation that would impact the safety of personal care products.
Breast Cancer Prevention Partners opposes the Accurate Labels Act (S.3019, H.R.6022) because it undermines transparency for consumers and undermines states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer goods.
FUTURE LEGISLATIVE PROPOSALS:
The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS).
REGULATION AND LEGISLATIVE INTENT:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
2/2/2017 LD2 Lobbying Disclosure Report
https://lda.congress.gov/LD/forms/ReportDisplay.aspx?t=2&s=1&i=1 3/4
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).
Agencies Lobbied
U.S. Senate
Lobbying Issues
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA.
CURRENT LEGISLATIVE PROPOSALS
The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products.
The Breast Cancer Prevention Partners supports reform and strengthening of the personal care products regulatory system, and is working to ensure strong, health protective measures are included in legislation such as S.1113, the Personal Care Products Safety Act, and any other legislation that would impact the safety of personal care products.
Breast Cancer Prevention Partners opposes the Accurate Labels Act (S.3019, H.R.6022) because it undermines transparency for consumers and undermines states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer goods.
FUTURE LEGISLATIVE PROPOSALS:
The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS).
REGULATION AND LEGISLATIVE INTENT:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
2/2/2017 LD2 Lobbying Disclosure Report
https://lda.congress.gov/LD/forms/ReportDisplay.aspx?t=2&s=1&i=1 3/4
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).
Agencies Lobbied
U.S. Senate
Type of Issue
Chemicals/Chemical Industry/Safety/Protection
Lobbying Issues
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA.
CURRENT LEGISLATIVE PROPOSALS
The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products.
The Breast Cancer Prevention Partners supports reform and strengthening of the personal care products regulatory system, and is working to ensure strong, health protective measures are included in legislation such as S.1113, the Personal Care Products Safety Act, and any other legislation that would impact the safety of personal care products.
Breast Cancer Prevention Partners opposes the Accurate Labels Act (S.3019, H.R.6022) because it undermines transparency for consumers and undermines states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer goods.
FUTURE LEGISLATIVE PROPOSALS:
The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS).
REGULATION AND LEGISLATIVE INTENT:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
2/2/2017 LD2 Lobbying Disclosure Report
https://lda.congress.gov/LD/forms/ReportDisplay.aspx?t=2&s=1&i=1 3/4
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, The Raben Group lobbied for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) , earning $10,000. The report was filed on April 20, 2018.
Original Filing: 300952596.xml
Lobbying Issues
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA.
CURRENT LEGISLATIVE PROPOSALS:
The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products.
The Breast Cancer Prevention Partners supports reform and strengthening of the personal care products regulatory system, and is working to ensure strong, health protective measures are included in legislation such as S.1113, the Personal Care Products Safety Act, and any other legislation that would impact the safety of personal care products.
FUTURE LEGISLATIVE PROPOSALS:
The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS).
REGULATION AND LEGISLATIVE INTENT:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
2/2/2017 LD2 Lobbying Disclosure Report
https://lda.congress.gov/LD/forms/ReportDisplay.aspx?t=2&s=1&i=1 3/4
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).
Agencies Lobbied
U.S. Senate
Lobbying Issues
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA.
CURRENT LEGISLATIVE PROPOSALS
The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products.
The Breast Cancer Prevention Partners supports reform and strengthening of the personal care products regulatory system, and is working to ensure strong, health protective measures are included in legislation such as S.1113, the Personal Care Products Safety Act, and any other legislation that would impact the safety of personal care products.
FUTURE LEGISLATIVE PROPOSALS:
The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS).
REGULATION AND LEGISLATIVE INTENT:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
2/2/2017 LD2 Lobbying Disclosure Report
https://lda.congress.gov/LD/forms/ReportDisplay.aspx?t=2&s=1&i=1 3/4
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).
Agencies Lobbied
U.S. Senate
Type of Issue
Chemicals/Chemical Industry/Safety/Protection/Superfund
4th Quarter, 2017
In Q4, The Raben Group lobbied for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) , earning $10,000. The report was filed on Jan. 18, 2018.
Original Filing: 300926863.xml
Lobbying Issues
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA.
CURRENT LEGISLATIVE PROPOSALS:
The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products.
FUTURE LEGISLATIVE PROPOSALS:
The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS).
REGULATION AND LEGISLATIVE INTENT:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
2/2/2017 LD2 Lobbying Disclosure Report
https://lda.congress.gov/LD/forms/ReportDisplay.aspx?t=2&s=1&i=1 3/4
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).
Agencies Lobbied
U.S. Senate
Lobbying Issues
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA.
CURRENT LEGISLATIVE PROPOSALS
The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products.
FUTURE LEGISLATIVE PROPOSALS:
The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS).
REGULATION AND LEGISLATIVE INTENT:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
2/2/2017 LD2 Lobbying Disclosure Report
https://lda.congress.gov/LD/forms/ReportDisplay.aspx?t=2&s=1&i=1 3/4
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).
Agencies Lobbied
U.S. Senate
Type of Issue
Chemicals/Chemical Industry/Safety/Protection/Superfund
3rd Quarter, 2017
In Q3, The Raben Group lobbied for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) , earning $10,000. The report was filed on Oct. 20, 2017.
Original Filing: 300911474.xml
Lobbying Issues
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA.
CURRENT LEGISLATIVE PROPOSALS:
The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products.
FUTURE LEGISLATIVE PROPOSALS:
The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS).
REGULATION AND LEGISLATIVE INTENT:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
2/2/2017 LD2 Lobbying Disclosure Report
https://lda.congress.gov/LD/forms/ReportDisplay.aspx?t=2&s=1&i=1 3/4
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).
Agencies Lobbied
U.S. Senate
Lobbying Issues
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA.
CURRENT LEGISLATIVE PROPOSALS
The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products.
FUTURE LEGISLATIVE PROPOSALS:
The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS).
REGULATION AND LEGISLATIVE INTENT:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
2/2/2017 LD2 Lobbying Disclosure Report
https://lda.congress.gov/LD/forms/ReportDisplay.aspx?t=2&s=1&i=1 3/4
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).
Agencies Lobbied
U.S. Senate
Type of Issue
Chemicals/Chemical Industry/Safety/Protection/Superfund
2nd Quarter, 2017
In Q2, The Raben Group lobbied for Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) , earning $10,000. The report was filed on July 20, 2017.
Original Filing: 300894674.xml
Lobbying Issues
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA.
CURRENT LEGISLATIVE PROPOSALS:
The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products.
FUTURE LEGISLATIVE PROPOSALS:
The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS).
REGULATION AND LEGISLATIVE INTENT:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
2/2/2017 LD2 Lobbying Disclosure Report
https://lda.congress.gov/LD/forms/ReportDisplay.aspx?t=2&s=1&i=1 3/4
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).
Agencies Lobbied
U.S. Senate
Lobbying Issues
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA.
CURRENT LEGISLATIVE PROPOSALS
The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products.
FUTURE LEGISLATIVE PROPOSALS:
The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS).
REGULATION AND LEGISLATIVE INTENT:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
2/2/2017 LD2 Lobbying Disclosure Report
https://lda.congress.gov/LD/forms/ReportDisplay.aspx?t=2&s=1&i=1 3/4
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).
Agencies Lobbied
U.S. Senate
Type of Issue
Chemicals/Chemical Industry/Safety/Protection/Superfund
1st Quarter, 2017
The Raben Group amended a lobbying report for representation of Breast Cancer Prevention Partners (formerly known as Breast Cancer Fund) in Q12017 on April 20, 2017.
Original Filing: 300877650.xml
Lobbying Issues
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
The Breast Cancer Fund contacted Senate offices about preserving the current Design for the Environment program in the EPA.
FUTURE LEGISLATIVE PROPOSALS:
The Breast Cancer Fund visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out
research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast
Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast
cancer (IBCERCC).
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate
product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials
from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health
risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Fund supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS).
REGULATION AND LEGISLATIVE INTENT:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Fund has also met with members of the FDA
management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
2/2/2017 LD2 Lobbying Disclosure Report
https://lda.congress.gov/LD/forms/ReportDisplay.aspx?t=2&s=1&i=1 3/4
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now
monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and
urging expeditious research and regulatory action as required by the legislation.
P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Fund is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic
Substances Control Act (TSCA).
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Chemical Industry/Safety/Protection/Superfund
1st Quarter, 2017
In Q1, The Raben Group lobbied for Breast Cancer Prevention Partners , earning $10,000. The report was filed on April 19, 2017.
Original Filing: 300871147.xml
Lobbying Issues
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
The Breast Cancer Fund contacted Senate offices about preserving the current Design for the Environment program in the EPA.
FUTURE LEGISLATIVE PROPOSALS:
The Breast Cancer Fund visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out
research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast
Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast
cancer (IBCERCC).
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate
product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials
from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health
risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Fund supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS).
REGULATION AND LEGISLATIVE INTENT:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Fund has also met with members of the FDA
management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
2/2/2017 LD2 Lobbying Disclosure Report
https://lda.congress.gov/LD/forms/ReportDisplay.aspx?t=2&s=1&i=1 3/4
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now
monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and
urging expeditious research and regulatory action as required by the legislation.
P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Fund is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic
Substances Control Act (TSCA).
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Chemical Industry/Safety/Protection/Superfund
4th Quarter, 2016
In Q4, The Raben Group lobbied for Breast Cancer Fund , earning $10,000. The report was filed on Jan. 21, 2017.
Original Filing: 300854008.xml
Lobbying Issues
Legislation in the 114th Congress:
S. 1014, Personal Care Products Safety Act
The Breast Cancer Fund continues to meet with staff from Senator Feinsteins office and other HELP committee offices to encourage legislative action on the issue of safety of Personal Care Products. The Breast Cancer Fund supports action that would effectively regulate Personal Care Products and Cosmetics to protect the health of consumers, workers, and communities. The Breast Cancer Fund also continues to meet with staff from House offices to encourage introduction of legislation in the House to reform the FDAs regulation of cosmetics and personal care product ingredients to prevent the use of chemicals found to have negative health and environmental impacts.
S. 725, Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
S. 821, BPA in Food Packaging Right to Know Act
The Breast Cancer Fund continues to meet with staff from Senate offices to encourage legislative action on the issue of bisphenol-A, which has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund supports action that would ban bisphenol-A from the linings of canned food, foods marketed to children, and food storage containers.
S. 3412, Ban Poisonous Additives Act of 2016
The Breast Cancer Fund supports this legislation that would ban bisphenol-A in food containers and prevent manufacturers from replacing bisphenol-A in food containers with unsafe alternatives because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems.
H.R. 6269, Ban Poisonous Additives Act of 2016
The Breast Cancer Fund supports this legislation that would ban bisphenol-A in food containers and prevent manufacturers from replacing bisphenol-A in food containers with unsafe alternatives because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems.
H.R. 5205, Cleaning Product Right to Know Act of 2016
The Breast Cancer Fund supports this bill that would require cleaning products to be labeled with all the ingredients contained therein. The Breast Cancer Fund has been meeting with House offices to urge Members to cosponsor the bill, and also with Senate offices to urge Senators to take up the issue in the Senate.
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
The Breast Cancer Fund contacted Senate offices about preserving the current Design for the Environment program in the EPA.
FUTURE LEGISLATIVE PROPOSALS:
The Breast Cancer Fund visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Fund supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS).
REGULATION AND LEGISLATIVE INTENT:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Fund has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Fund is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, The Raben Group lobbied for Breast Cancer Fund , earning $10,000. The report was filed on Oct. 20, 2016.
Original Filing: 300839393.xml
Lobbying Issues
Legislation in the 114th Congress:
S. 1014, Personal Care Products Safety Act
The Breast Cancer Fund continues to meet with staff from Senator Feinsteins office and other HELP committee offices to encourage legislative action on the issue of safety of Personal Care Products. The Breast Cancer Fund supports action that would effectively regulate Personal Care Products and Cosmetics to protect the health of consumers, workers, and communities. The Breast Cancer Fund also continues to meet with staff from House offices to encourage introduction of legislation in the House to reform the FDAs regulation of cosmetics and personal care product ingredients to prevent the use of chemicals found to have negative health and environmental impacts.
S. 725, Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
S. 821, BPA in Food Packaging Right to Know Act
The Breast Cancer Fund continues to meet with staff from Senate offices to encourage legislative action on the issue of bisphenol-A, which has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund supports action that would ban bisphenol-A from the linings of canned food, foods marketed to children, and food storage containers.
S. 3412, Ban Poisonous Additives Act of 2016
The Breast Cancer Fund supports this legislation that would ban bisphenol-A in food containers and prevent manufacturers from replacing bisphenol-A in food containers with unsafe alternatives because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems.
H.R. 6269, Ban Poisonous Additives Act of 2016
The Breast Cancer Fund supports this legislation that would ban bisphenol-A in food containers and prevent manufacturers from replacing bisphenol-A in food containers with unsafe alternatives because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems.
H.R. 5205, Cleaning Product Right to Know Act of 2016
The Breast Cancer Fund supports this bill that would require cleaning products to be labeled with all the ingredients contained therein. The Breast Cancer Fund has been meeting with House offices to urge Members to cosponsor the bill, and also with Senate offices to urge Senators to take up the issue in the Senate.
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
The Breast Cancer Fund contacted Senate offices about preserving the current Design for the Environment program in the EPA.
FUTURE LEGISLATIVE PROPOSALS:
The Breast Cancer Fund visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Fund supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS).
REGULATION AND LEGISLATIVE INTENT:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Fund has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Fund is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, The Raben Group lobbied for Breast Cancer Fund , earning $10,000. The report was filed on July 29, 2016.
Original Filing: 300822991.xml
Lobbying Issues
LEGISLATION IN THE 114TH CONGRESS
S.1014, Personal Care Products Safety Act
The Breast Cancer Fund continues to meet with staff from Senator Feinsteins office and other HELP committee offices to encourage legislative action on the issue of safety of Personal Care Products. The Breast Cancer Fund supports action that would remove toxins and regulate Personal Care Products and Cosmetics.
H.R.2576, TSCA Modernization Act of 2015
The Breast Cancer Fund supports this bill and has been meeting with House and Senate offices to persuade members to take up the bill in the Senate.
S. 697, Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Fund opposes this legislation without amendments, as it would do little to strengthen the current TSCA law, but continues to work with members of the Senate Committee on Environment and Public Works to improve and strengthen the bill.
S. 725, Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
S. 821, BPA in Food Packaging Right to Know Act
The Breast Cancer Fund continues to meet with staff from Senate offices to encourage legislative action on the issue of bisphenol-A, which has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund support action that would ban bisphenol-A from the linings of canned food, foods marketed to children, and food storage containers.
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
The Breast Cancer Fund contacted Senate offices about preserving the current Design for the Environment program in the EPA.
FUTURE LEGISLATIVE PROPOSALS:
The Breast Cancer Fund visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic and personal care product ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Fund continues to talk with staff from Senate offices about the introduction of legislation in the Senate to reform the FDAs regulation of cosmetics and personal care product ingredients to prevent the use of chemicals found to have negative health and environmental impacts.
REGULATION AND LEGISLATIVE INTENT:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Fund has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
Lobbying: U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Consumer Product Safety Commission (CPSC), National Institutes of Health (NIH), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Office of Management & Budget (OMB), Health & Human Services - Department of (HHS), Office of Science & Technology Policy (OSTP), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, The Raben Group lobbied for Breast Cancer Fund , earning $10,000. The report was filed on April 20, 2016.
Original Filing: 300803712.xml
Lobbying Issues
LEGISLATION IN THE 114TH CONGRESS
S.1014, Personal Care Products Safety Act
The Breast Cancer Fund continues to meet with staff from Senator Feinsteins office and other HELP committee offices to encourage legislative action on the issue of safety of Personal Care Products. The Breast Cancer Fund supports action that would remove toxins and regulate Personal Care Products and Cosmetics.
H.R.2576, TSCA Modernization Act of 2015
The Breast Cancer Fund supports this bill and has been meeting with House and Senate offices to persuade members to take up the bill in the Senate.
S. 697, Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Fund opposes this legislation without amendments, as it would do little to strengthen the current TSCA law, but continues to work with members of the Senate Committee on Environment and Public Works to improve and strengthen the bill.
S. 725, Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
S. 821, BPA in Food Packaging Right to Know Act
The Breast Cancer Fund continues to meet with staff from Senate offices to encourage legislative action on the issue of bisphenol-A, which has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund support action that would ban bisphenol-A from the linings of canned food, foods marketed to children, and food storage containers.
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
The Breast Cancer Fund contacted Senate offices about preserving the current Design for the Environment program in the EPA.
FUTURE LEGISLATIVE PROPOSALS:
The Breast Cancer Fund visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic and personal care product ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Fund continues to talk with staff from Senate offices about the introduction of legislation in the Senate to reform the FDAs regulation of cosmetics and personal care product ingredients to prevent the use of chemicals found to have negative health and environmental impacts.
REGULATION AND LEGISLATIVE INTENT:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Fund has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
Lobbying: U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Consumer Product Safety Commission (CPSC), National Institutes of Health (NIH), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Office of Management & Budget (OMB), Health & Human Services - Department of (HHS), Office of Science & Technology Policy (OSTP), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, The Raben Group lobbied for Breast Cancer Fund , earning $10,000. The report was filed on Jan. 20, 2016.
Original Filing: 300784484.xml
Lobbying Issues
LEGISLATION IN THE 114TH CONGRESS
S.1014, Personal Care Products Safety Act
The Breast Cancer Fund continues to meet with staff from Senator Feinsteins office and other HELP committee offices to encourage legislative action on the issue of safety of Personal Care Products. The Breast Cancer Fund supports action that would remove toxins and regulate Personal Care Products and Cosmetics.
H.R.2576, TSCA Modernization Act of 2015
The Breast Cancer Fund supports this bill and has been meeting with House and Senate offices to persuade members to take up the bill in the Senate.
S. 697, Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Fund opposes this legislation without amendments, as it would do little to strengthen the current TSCA law, but continues to work with members of the Senate Committee on Environment and Public Works to improve and strengthen the bill.
S. 725, Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
S. 821, BPA in Food Packaging Right to Know Act
The Breast Cancer Fund continues to meet with staff from Senate offices to encourage legislative action on the issue of bisphenol-A, which has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund support action that would ban bisphenol-A from the linings of canned food, foods marketed to children, and food storage containers.
H.R.1735, National Defense Authorization Act for FY2016 (NDAA)
The Breast Cancer Fund supports an amendment to NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
The Breast Cancer Fund contacted Senate offices about preserving the current Design for the Environment program in the EPA.
FUTURE LEGISLATIVE PROPOSALS:
The Breast Cancer Fund visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic and personal care product ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Fund continues to talk with staff from Senate offices about the introduction of legislation in the Senate to reform the FDAs regulation of cosmetics and personal care product ingredients to prevent the use of chemicals found to have negative health and environmental impacts.
REGULATION AND LEGISLATIVE INTENT:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Fund has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
Lobbying: U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Consumer Product Safety Commission (CPSC), National Institutes of Health (NIH), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Office of Management & Budget (OMB), Health & Human Services - Department of (HHS), Office of Science & Technology Policy (OSTP), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, The Raben Group lobbied for Breast Cancer Fund , earning $10,000. The report was filed on Oct. 20, 2015.
Original Filing: 300761262.xml
Lobbying Issues
LEGISLATION IN THE 114TH CONGRESS
S.1014, Personal Care Products Safety Act
The Breast Cancer Fund continues to meet with staff from Senator Feinsteins office and other HELP committee offices to encourage legislative action on the issue of safety of Personal Care Products. The Breast Cancer Fund supports action that would remove toxins and regulate Personal Care Products and Cosmetics.
H.R.2576, TSCA Modernization Act of 2015
The Breast Cancer Fund supports this bill and has been meeting with House and Senate offices to persuade members to take up the bill in the Senate.
S. 697, Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Fund opposes this legislation without amendments, as it would do little to strengthen the current TSCA law, but continues to work with members of the Senate Committee on Environment and Public Works to improve and strengthen the bill.
S. 725, Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
S. 821, BPA in Food Packaging Right to Know Act
The Breast Cancer Fund continues to meet with staff from Senate offices to encourage legislative action on the issue of bisphenol-A, which has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund support action that would ban bisphenol-A from the linings of canned food, foods marketed to children, and food storage containers.
H.R.1735, National Defense Authorization Act for FY2016 (NDAA)
The Breast Cancer Fund supports an amendment to NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
The Breast Cancer Fund contacted Senate offices about preserving the current Design for the Environment program in the EPA.
FUTURE LEGISLATIVE PROPOSALS:
The Breast Cancer Fund visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic and personal care product ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Fund continues to talk with staff from Senate offices about the introduction of legislation in the Senate to reform the FDAs regulation of cosmetics and personal care product ingredients to prevent the use of chemicals found to have negative health and environmental impacts.
REGULATION AND LEGISLATIVE INTENT:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Fund has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
Lobbying: U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Consumer Product Safety Commission (CPSC), National Institutes of Health (NIH), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Office of Management & Budget (OMB), Health & Human Services - Department of (HHS), Office of Science & Technology Policy (OSTP), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
The Raben Group amended a lobbying report for representation of Breast Cancer Fund in Q32015 on Oct. 20, 2015.
Original Filing: 300761296.xml
Lobbying Issues
LEGISLATION IN THE 114TH CONGRESS
S.1014, Personal Care Products Safety Act
The Breast Cancer Fund continues to meet with staff from Senator Feinsteins office and other HELP committee offices to encourage legislative action on the issue of safety of Personal Care Products. The Breast Cancer Fund supports action that would remove toxins and regulate Personal Care Products and Cosmetics.
H.R.2576, TSCA Modernization Act of 2015
The Breast Cancer Fund supports this bill and has been meeting with House and Senate offices to persuade members to take up the bill in the Senate.
S. 697, Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Fund opposes this legislation without amendments, as it would do little to strengthen the current TSCA law, but continues to work with members of the Senate Committee on Environment and Public Works to improve and strengthen the bill.
S. 725, Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
S. 821, BPA in Food Packaging Right to Know Act
The Breast Cancer Fund continues to meet with staff from Senate offices to encourage legislative action on the issue of bisphenol-A, which has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund support action that would ban bisphenol-A from the linings of canned food, foods marketed to children, and food storage containers.
H.R.1735, National Defense Authorization Act for FY2016 (NDAA)
The Breast Cancer Fund supports an amendment to NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
The Breast Cancer Fund contacted Senate offices about preserving the current Design for the Environment program in the EPA.
FUTURE LEGISLATIVE PROPOSALS:
The Breast Cancer Fund visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic and personal care product ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Fund continues to talk with staff from Senate offices about the introduction of legislation in the Senate to reform the FDAs regulation of cosmetics and personal care product ingredients to prevent the use of chemicals found to have negative health and environmental impacts.
REGULATION AND LEGISLATIVE INTENT:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Fund has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
Lobbying: U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Consumer Product Safety Commission (CPSC), National Institutes of Health (NIH), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Office of Management & Budget (OMB), Health & Human Services - Department of (HHS), Office of Science & Technology Policy (OSTP), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
In Q2, The Raben Group lobbied for Breast Cancer Fund , earning $10,000. The report was filed on July 20, 2015.
Original Filing: 300746246.xml
Lobbying Issues
LEGISLATION IN THE 114TH CONGRESS
S.1014, Personal Care Products Safety Act
The Breast Cancer Fund continues to meet with staff from Senator Feinsteins office and other HELP committee offices to encourage legislative action on the issue of safety of Personal Care Products. The Breast Cancer Fund supports action that would remove toxins and regulate Personal Care Products and Cosmetics.
H.R.2576, TSCA Modernization Act of 2015
The Breast Cancer Fund supports this bill and has been meeting with House and Senate offices to persuade members to take up the bill in the Senate.
S. 697, Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Fund opposes this legislation without amendments, as it would do little to strengthen the current TSCA law, but continues to work with members of the Senate Committee on Environment and Public Works to improve and strengthen the bill.
S. 725, Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
S. 821, BPA in Food Packaging Right to Know Act
The Breast Cancer Fund continues to meet with staff from Senate offices to encourage legislative action on the issue of bisphenol-A, which has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund support action that would ban bisphenol-A from the linings of canned food, foods marketed to children, and food storage containers.
H.R.1735, National Defense Authorization Act for FY2016 (NDAA)
The Breast Cancer Fund supports an amendment to NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
HOUSE AND SENATE APPROPRIATIONS
The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
National Institute of Environmental Health Sciences (NIEHS)
The Breast Cancer Fund contacted Senate offices about preserving the current Design for the Environment program in the EPA.
FUTURE LEGISLATIVE PROPOSALS:
The Breast Cancer Fund visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic and personal care product ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Fund continues to talk with staff from Senate offices about the introduction of legislation in the Senate to reform the FDAs regulation of cosmetics and personal care product ingredients to prevent the use of chemicals found to have negative health and environmental impacts.
REGULATION AND LEGISLATIVE INTENT:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Fund has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
Lobbying: U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Consumer Product Safety Commission (CPSC), National Institutes of Health (NIH), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Office of Management & Budget (OMB), Health & Human Services - Department of (HHS), Office of Science & Technology Policy (OSTP), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, The Raben Group lobbied for Breast Cancer Fund , earning $10,000. The report was filed on April 21, 2015.
Original Filing: 300728097.xml
Lobbying Issues
Legislation in the 114th
S. 697, Frank R. Lautenberg Chemical Safety for the 21st Century Act
The Breast Cancer Fund opposes this legislation in its current form, as it would do little to strengthen the current TSCA law, but continues to work with members of the Senate Committee on Environment and Public Works to improve and strengthen the bill.
S. 725, Alan Reinstein and Trevor Schaefer Toxic Chemical Protection Act
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
S. 821, BPA in Food Packaging Right to Know Act
The Breast Cancer Fund continues to meet with staff from Senate offices to encourage legislative action on the issue of bisphenol-A, which has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund support action that would ban bisphenol-A from the linings of canned food, foods marketed to children, and food storage containers.
House and Senate Appropriations
The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for the following:
Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program
Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network
National Institute of Environmental Health Sciences (NIEHS)
H.R.1735, National Defense Authorization Act for FY2016 (NDAA)
The Breast Cancer Fund supports an amendment to NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
Future Legislative Proposals:
The Breast Cancer Fund visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic and personal care product ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Fund continues to talk with staff from Senate offices about the introduction of legislation in the Senate to reform the FDAs regulation of cosmetics and personal care product ingredients to prevent the use of chemicals found to have negative health and environmental impacts.
Regulation and Legislative Intent:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Fund has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
P.L. 110-314 - The Consumer Product Safety Commission Improvement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, The Raben Group lobbied for Breast Cancer Fund , earning $10,000. The report was filed on Feb. 6, 2015.
Original Filing: 300710563.xml
Lobbying Issues
Legislation in the 113th
Please see additional page for lobbying issues:S. 1009, the Chemical Safety Improvement Act of 2013
The Breast Cancer Fund opposes this legislation in its current form as it would do little to strengthen the current TSCA law, but continues to work with members of the Senate Committee on Environment and Public Works to improve and strengthen the bill.
S. 696, the Safe Chemicals Act of 2013
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
H.R. 1385, the Safe Cosmetics and Personal Care Products Act of 2013
The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic and personal care product ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
House and Senate Appropriations The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for the CDCs environmental health grants programs and for NIEHS programs related to breast cancer research.
H.R.4435, National Defense Authorization Act for FY2015 (NDAA)
The Breast Cancer Fund supports an amendment to NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation
activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
S.2410, National Defense Authorization Act for FY2015 (NDAA)
The Breast Cancer Fund supports an amendment to NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation
activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
Future Legislative Proposals:
The Breast Cancer Fund continues to meet with staff from Senate offices to encourage legislative action on the issue of bisphenol-A which has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund support action that would ban bisphenol-A from the linings of canned food, foods marketed to children, and food storage containers.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Fund continues to talk with staff from Senate offices about the introduction of legislation in the Senate to reform the FDAs regulation of cosmetics and personal care product ingredients to prevent the use of chemicals found to have negative health and environmental impacts.
Regulation and Legislative Intent:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Fund has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
P.L. 110-314 The Consumer Product Safety Commission Improvement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2014
In Q3, The Raben Group lobbied for Breast Cancer Fund , earning $10,000. The report was filed on Oct. 19, 2014.
Original Filing: 300682569.xml
Lobbying Issues
Legislation in the 113th
Please see additional page for lobbying issues:S. 1009, the Chemical Safety Improvement Act of 2013
The Breast Cancer Fund opposes this legislation in its current form as it would do little to strengthen the current TSCA law, but continues to work with members of the Senate Committee on Environment and Public Works to improve and strengthen the bill.
S. 696, the Safe Chemicals Act of 2013
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
H.R. 1385, the Safe Cosmetics and Personal Care Products Act of 2013
The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic and personal care product ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
House and Senate Appropriations The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for the CDCs environmental health grants programs and for NIEHS programs related to breast cancer research.
H.R.4435, National Defense Authorization Act for FY2015 (NDAA)
The Breast Cancer Fund supports an amendment to NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation
activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
S.2410, National Defense Authorization Act for FY2015 (NDAA)
The Breast Cancer Fund supports an amendment to NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation
activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC).
Future Legislative Proposals:
The Breast Cancer Fund continues to meet with staff from Senate offices to encourage legislative action on the issue of bisphenol-A which has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund support action that would ban bisphenol-A from the linings of canned food, foods marketed to children, and food storage containers.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Fund continues to talk with staff from Senate offices about the introduction of legislation in the Senate to reform the FDAs regulation of cosmetics and personal care product ingredients to prevent the use of chemicals found to have negative health and environmental impacts.
Regulation and Legislative Intent:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Fund has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
P.L. 110-314 The Consumer Product Safety Commission Improvement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2014
In Q2, The Raben Group lobbied for Breast Cancer Fund , earning $10,000. The report was filed on July 18, 2014.
Original Filing: 300660882.xml
Lobbying Issues
Legislation in the 113th
Please see additional page for lobbying issues:S. 1009, the Chemical Safety Improvement Act of 2013
The Breast Cancer Fund opposes this legislation in its current form as it would do little to strengthen the current TSCA law, but continues to work with members of the Senate Committee on Environment and Public Works to improve and strengthen the bill.
S. 696, the Safe Chemicals Act of 2013
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
H.R. 1385, the Safe Cosmetics and Personal Care Products Act of 2013
The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic and personal care product ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
House and Senate Appropriations The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for the CDCs environmental health grants programs and for NIEHS programs related to breast cancer research.
Future Legislative Proposals:
The Breast Cancer Fund continues to meet with staff from Senate offices to encourage legislative action on the issue of bisphenol-A which has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund support action that would ban bisphenol-A from the linings of canned food, foods marketed to children, and food storage containers.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Fund continues to talk with staff from Senate offices about the introduction of legislation in the Senate to reform the FDAs regulation of cosmetics and personal care product ingredients to prevent the use of chemicals found to have negative health and environmental impacts.
Regulation and Legislative Intent:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Fund has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
P.L. 110-314 The Consumer Product Safety Commission Improvement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2014
In Q1, The Raben Group lobbied for Breast Cancer Fund . The report was filed on April 18, 2014.
Original Filing: 300646513.xml
Lobbying Issues
Legislation in the 113th
Please see additional page for lobbying issues:S. 1009, the Chemical Safety Improvement Act of 2013
The Breast Cancer Fund opposes this legislation in its current form as it would do little to strengthen the current TSCA law, but continues to work with members of the Senate Committee on Environment and Public Works to improve and strengthen the bill.
S. 696, the Safe Chemicals Act of 2013
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
H.R. 1385, the Safe Cosmetics and Personal Care Products Act of 2013
The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic and personal care product ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
House and Senate Appropriations The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for the CDCs environmental health grants programs and for NIEHS programs related to breast cancer research.
Future Legislative Proposals:
The Breast Cancer Fund continues to meet with staff from Senate offices to encourage legislative action on the issue of bisphenol-A which has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund support action that would ban bisphenol-A from the linings of canned food, foods marketed to children, and food storage containers.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Fund continues to talk with staff from Senate offices about the introduction of legislation in the Senate to reform the FDAs regulation of cosmetics and personal care product ingredients to prevent the use of chemicals found to have negative health and environmental impacts.
Regulation and Legislative Intent:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Fund has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
P.L. 110-314 The Consumer Product Safety Commission Improvement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2013
In Q4, The Raben Group lobbied for Breast Cancer Fund . The report was filed on Jan. 20, 2014.
Original Filing: 300621130.xml
Lobbying Issues
Legislation in the 113th
Please see additional page for lobbying issues:S. 1009, the Chemical Safety Improvement Act of 2013
The Breast Cancer Fund opposes this legislation in its current form as it would do little to strengthen the current TSCA law, but continues to work with members of the Senate Committee on Environment and Public Works to improve and strengthen the bill.
S. 696, the Safe Chemicals Act of 2013
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
H.R. 1385, the Safe Cosmetics and Personal Care Products Act of 2013
The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic and personal care product ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
House and Senate Appropriations The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program, and increasing support for health tracking and NIEHS programs related to breast cancer research.
Future Legislative Proposals:
The Breast Cancer Fund continues to meet with staff from Senate offices to encourage legislative action on the issue of bisphenol-A which has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund support action that would ban bisphenol-A from the linings of canned food, foods marketed to children, and food storage containers.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Fund continues to talk with staff from Senate offices about the introduction of legislation in the Senate to reform the FDAs regulation of cosmetics and personal care product ingredients to prevent the use of chemicals found to have negative health and environmental impacts.
Regulation and Legislative Intent:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Fund has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
P.L. 110-314 The Consumer Product Safety Commission Improvement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2013
In Q3, The Raben Group lobbied for Breast Cancer Fund . The report was filed on Oct. 18, 2013.
Original Filing: 300604188.xml
Lobbying Issues
Legislation in the 113th
Please see additional page for lobbying issues:S. 1009, the Chemical Safety Improvement Act of 2013
The Breast Cancer Fund opposes this legislation in its current form as it would do little to strengthen the current TSCA law, but continues to work with members of the Senate Committee on Environment and Public Works to improve and strengthen the bill.
S. 696, the Safe Chemicals Act of 2013
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
H.R. 1385, the Safe Cosmetics and Personal Care Products Act of 2013
The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic and personal care product ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
House and Senate Appropriations The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program, and increasing support for health tracking and NIEHS programs related to breast cancer research.
Future Legislative Proposals:
The Breast Cancer Fund continues to meet with staff from Senate offices to encourage legislative action on the issue of bisphenol-A which has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund support action that would ban bisphenol-A from the linings of canned food, foods marketed to children, and food storage containers.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
The Breast Cancer Fund continues to talk with staff from Senate offices about the introduction of legislation in the Senate to reform the FDAs regulation of cosmetics and personal care product ingredients to prevent the use of chemicals found to have negative health and environmental impacts.
Regulation and Legislative Intent:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Fund has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally.
P.L. 110-314 The Consumer Product Safety Commission Improvement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2013
In Q2, The Raben Group lobbied for Breast Cancer Fund , earning $30,000. The report was filed on July 19, 2013.
Original Filing: 300578885.xml
Lobbying Issues
Legislation in the 113th
Please see additional page for lobbying issues:S. 696, the Safe Chemicals Act of 2013
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
H.R. 1385, the Safe Cosmetics and Personal Care Products Act of 2013
The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic and personal care product ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
House and Senate Appropriations The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program, and increasing support for health tracking and NIEHS programs related to breast cancer research.
Future Legislative Proposals:
The Breast Cancer Fund continues to meet with staff from Senate offices to encourage legislative action on the issue of bisphenol-A which has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund support action that would ban bisphenol-A from the linings of canned food, foods marketed to children, and food storage containers
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
Regulation and Legislative Intent:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally.
P.L. 110-314 The Consumer Product Safety Commission Improvement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2013
In Q1, The Raben Group lobbied for Breast Cancer Fund , earning $30,000. The report was filed on April 22, 2013.
Original Filing: 300563960.xml
Lobbying Issues
Legislation in the 113th
Please see additional page for lobbying issues:S. 696, the Safe Chemicals Act of 2013
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
H.R. 1385, the Safe Cosmetics and Personal Care Products Act of 2013
The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic and personal care product ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
House and Senate Appropriations The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program, and increasing support for health tracking and NIEHS programs related to breast cancer research.
Future Legislative Proposals:
The Breast Cancer Fund continues to meet with staff from Senate offices to encourage legislative action on the issue of bisphenol-A which has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund support action that would ban bisphenol-A from the linings of canned food, foods marketed to children, and food storage containers
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
Regulation and Legislative Intent:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally.
P.L. 110-314 The Consumer Product Safety Commission Improvement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
In Q4, The Raben Group lobbied for Breast Cancer Fund , earning $30,000. The report was filed on Jan. 22, 2013.
Original Filing: 300542398.xml
Lobbying Issues
Legislation in the 112th
H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill.Continued: Legislation in the 112th
S. 847, the Safe Chemicals Act of 2011
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
H.R. 2359, the Safe Cosmetics Act of 2011
The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
H.R.4395, the Cosmetic Safety Amendments Act of 2012
The Breast Cancer Fund opposes this legislation as it would further weaken the FDAs ability to regulate the safety of cosmetics.
H.R. 4262, the Cosmetics Safety Enhancement Act of 2012
The Breast Cancer Fund opposes this legislation as it is not strong enough to effectively regulate the safety of cosmetics.
H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and
H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011
The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer.
H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011.
The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely.
H.R. 3067: Accelerating the End of Breast Cancer Act of 2011.
The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner.
S. 3237, the Accelerating the End of Breast Cancer Act of 2012.
The Breast Cancer Fund supports this legislation as it would increase focus on research to prevent, treat, and end breast cancer.
House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program, opposing appropriations riders limiting the work of the National Toxicology Program's Report on Carcinogens, and increasing support for health tracking and NIEHS programs related to breast cancer research.
Future Legislative Proposals:
The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
Regulation and Legislative Intent:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally.
Presidents Cancer Panel Report
The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment.
P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation.
P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008
This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, The Raben Group lobbied for Breast Cancer Fund , earning $30,000. The report was filed on Oct. 22, 2012.
Original Filing: 300519381.xml
Lobbying Issues
Legislation in the 112th
H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill.Continued: Legislation in the 112th
S. 847, the Safe Chemicals Act of 2011
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
H.R. 2359, the Safe Cosmetics Act of 2011
The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
H.R.4395, the Cosmetic Safety Amendments Act of 2012
The Breast Cancer Fund opposes this legislation as it would further weaken the FDAs ability to regulate the safety of cosmetics.
H.R. 4262, the Cosmetics Safety Enhancement Act of 2012
The Breast Cancer Fund opposes this legislation as it is not strong enough to effectively regulate the safety of cosmetics.
H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and
H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011
The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer.
H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011.
The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely.
H.R. 3067: Accelerating the End of Breast Cancer Act of 2011.
The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner.
S. 3237, the Accelerating the End of Breast Cancer Act of 2012.
The Breast Cancer Fund supports this legislation as it would increase focus on research to prevent, treat, and end breast cancer.
House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program, opposing appropriations riders limiting the work of the National Toxicology Program's Report on Carcinogens, and increasing support for health tracking and NIEHS programs related to breast cancer research.
Future Legislative Proposals:
The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
Regulation and Legislative Intent:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally.
Presidents Cancer Panel Report
The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment.
P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation.
P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008
This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, The Raben Group lobbied for Breast Cancer Fund , earning $30,000. The report was filed on July 19, 2012.
Original Filing: 300493208.xml
Lobbying Issues
Legislation in the 112th
H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill.Continued: Legislation in the 112th
S. 847, the Safe Chemicals Act of 2011
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
H.R. 2359, the Safe Cosmetics Act of 2011
The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
H.R.4395, the Cosmetic Safety Amendments Act of 2012
The Breast Cancer Fund opposes this legislation as it would further weaken the FDAs ability to regulate the safety of cosmetics.
H.R. 4262, the Cosmetics Safety Enhancement Act of 2012
The Breast Cancer Fund opposes this legislation as it is not strong enough to effectively regulate the safety of cosmetics.
H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and
H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011
The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer.
H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011.
The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely.
H.R. 3067: Accelerating the End of Breast Cancer Act of 2011.
The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner.
S. 3237, the Accelerating the End of Breast Cancer Act of 2012.
The Breast Cancer Fund supports this legislation as it would increase focus on research to prevent, treat, and end breast cancer.
House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research.
Future Legislative Proposals:
The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
Regulation and Legislative Intent:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally.
Presidents Cancer Panel Report
The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment.
P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation.
P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008
This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2012
In Q1, The Raben Group lobbied for Breast Cancer Fund , earning $30,000. The report was filed on April 20, 2012.
Original Filing: 300469664.xml
Lobbying Issues
Legislation in the 112th
H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill.Continued: Legislation in the 112th
S. 847, the Safe Chemicals Act of 2011
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
H.R. 2359, the Safe Cosmetics Act of 2011
The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and
H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011
The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer.
H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011.
The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely.
H.R. 3067: Accelerating the End of Breast Cancer Act of 2011.
The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner.
House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research.
Future Legislative Proposals:
The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
Regulation and Legislative Intent:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally.
Presidents Cancer Panel Report
The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment.
P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation.
P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008
This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2011
In Q4, The Raben Group lobbied for Breast Cancer Fund , earning $30,000. The report was filed on Jan. 20, 2012.
Original Filing: 300446399.xml
Lobbying Issues
Legislation in the 112th
H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill.Continued: Legislation in the 112th
S. 847, the Safe Chemicals Act of 2011
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
H.R. 2359, the Safe Cosmetics Act of 2011
The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and
H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011
The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer.
H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011.
The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely.
H.R. 3067: Accelerating the End of Breast Cancer Act of 2011.
The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner.
House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research.
Future Legislative Proposals:
The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
Regulation and Legislative Intent:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally.
Presidents Cancer Panel Report
The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment.
P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation.
P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008
This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2011
In Q3, The Raben Group lobbied for Breast Cancer Fund , earning $30,000. The report was filed on Oct. 20, 2011.
Original Filing: 300427990.xml
Lobbying Issues
Legislation in the 112th
H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill.Continued: Legislation in the 112th
S. 847, the Safe Chemicals Act of 2011
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
H.R. 2359, the Safe Cosmetics Act of 2011
The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and
H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011
The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer.
H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011.
The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely.
House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research.
Future Legislative Proposals:
The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
Regulation and Legislative Intent:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally.
Presidents Cancer Panel Report
The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment.
P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation.
P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008
This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2011
In Q2, The Raben Group lobbied for Breast Cancer Fund , earning $30,000. The report was filed on July 20, 2011.
Original Filing: 300401971.xml
Lobbying Issues
Legislation in the 112th
H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill.Continued: Legislation in the 112th
S. 847, the Safe Chemicals Act of 2011
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
H.R. 2359, the Safe Cosmetics Act of 2011
The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and
H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011
The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer.
H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011.
The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely.
House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research.
Future Legislative Proposals:
The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
Regulation and Legislative Intent:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally.
Presidents Cancer Panel Report
The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel.
P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation.
P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008
This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2011
In Q1, The Raben Group lobbied for Breast Cancer Fund , earning $30,000. The report was filed on April 19, 2011.
Original Filing: 300372645.xml
Lobbying Issues
Legislation in the 112th
H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill.Continued: Legislation in the 112th
House and Senate Appropriations The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research.
H.R. 553, Endocrine Disruptor Screening Enhancement Act of 2011. The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer.
Future Legislative Proposals:
The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
Regulation and Legislative Intent:
FDA Advocacy, In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally.
Presidents Cancer Panel Report, The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel.
P.L. 110-314, The Consumer Product Safety Commission Improvement Act, The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation.
P.L. 110-354, Breast Cancer and Environmental Research Act of 2008, This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2010
In Q4, The Raben Group lobbied for Breast Cancer Fund , earning $40,000. The report was filed on Jan. 18, 2011.
Original Filing: 300346725.xml
Lobbying Issues
Legislation in the 111th
H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill.Continued: Legislation in the 111th
H.R. 2751, FDA Food Safety Modernization Act (Senate version S. 510)
The Breast Cancer Fund supported efforts to pass this legislation because of a possible amendment to ban bisphenol-A, a chemical linked to increased rates of cancer, as well as other significant health problems, from certain food contact materials. The Breast Cancer Fund met with staff from various offices to encourage support for this language and eventual passage of the bill.
House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research.
H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697)
The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828)
The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer.
H.R. 5820 The Safe Chemicals Act of 2010 (Senate version 3209)
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
H.R. 5786 Safe Cosmetics Act of 2010 (Senate version not yet introduced)
The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
Future Legislative Proposals:
The Breast Cancer Fund continues to meet with staff from various Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
Regulation and Legislative Intent:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally.
Presidents Cancer Panel Report
The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel.
P.L. 110-314 The Consumer Product Safety Commission Improvement Act
This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation.
P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008
This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2010
In Q3, The Raben Group lobbied for Breast Cancer Fund , earning $40,000. The report was filed on Oct. 20, 2010.
Original Filing: 300325188.xml
Lobbying Issues
Legislation in the 111th
H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill.Continued: Legislation in the 111th
House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research.
H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697)
The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828)
The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer.
H.R. 5820 The Safe Chemicals Act of 2010 (Senate version 3209)
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
H.R. 5786 Safe Cosmetics Act of 2010 (Senate version not yet introduced)
The Breast Cancer Fund supports this legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
Future Legislative Proposals:
The Breast Cancer Fund continues to meet with staff from various Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
Regulation and Legislative Intent:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report
The Breast Cancer Fund provided educational briefings to staff within the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the Presidents Cancer Panel.
P.L. 110-314 The Consumer Product Safety Commission Improvement Act
This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation.
P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008
This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2010
In Q2, The Raben Group lobbied for Breast Cancer Fund , earning $40,000. The report was filed on July 20, 2010.
Original Filing: 300303573.xml
Lobbying Issues
Legislation in the 111th
H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593)
Continued: Legislation in the 111th
H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593)
The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill.
House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research.
H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697)
The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828)
The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer.
Future Legislative Proposals:
The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
The Breast Cancer Fund has met with staff from various House and Senate offices about future legislation to reform the Estrogenic Substances Screening Program at EPA with the goal of identifying and removing estrogenic compounds in our nations drinking supply that currently increase the risk of breast cancer incidence.
Regulation and Legislative Intent:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally.
P.L. 110-314 The Consumer Product Safety Commission Improvement Act
This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation.
P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008
This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.
S.3209, the Safe Chemicals Act of 2010 (House bill not yet introduced). The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2010
In Q1, The Raben Group lobbied for Breast Cancer Fund , earning $40,000. The report was filed on April 20, 2010.
Original Filing: 300273114.xml
Lobbying Issues
Legislation in the 111th
H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593)
Continued: Legislation in the 111th
H.R. 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593)
The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill.
House and Senate Appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research.
H.R. 3057 Household Product Labeling Act of 2009 (Senate version S. 1697)
The Breast Cancer Fund supports this legislation because complete and accurate product labeling of chemicals used in consumer products is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
H.R. 4190 Endocrine Disruption Prevention Act of 2009(Senate version S. 2828)
The Breast Cancer Fund supports this legislation as it will increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer.
Future Legislative Proposals:
The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
The Breast Cancer Fund has met with staff from various House and Senate offices about future legislation to reform the Estrogenic Substances Screening Program at EPA with the goal of identifying and removing estrogenic compounds in our nations drinking supply that currently increase the risk of breast cancer incidence.
Regulation and Legislative Intent:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally.
P.L. 110-314 The Consumer Product Safety Commission Improvement Act
This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation.
P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008
This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2009
In Q4, The Raben Group lobbied for Breast Cancer Fund , earning $40,000. The report was filed on Jan. 18, 2010.
Original Filing: 300239086.xml
Lobbying Issues
Legislation in the 111th
HR1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation in the 111th
HR 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593)
The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill.
House and Senate appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC.
Future Legislative Proposals
The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
Regulation and Legislative Intent
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally.
P.L. 110-314 The Consumer Product Safety Commission Improvement Act
This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation.
P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008
This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2009
In Q3, The Raben Group lobbied for Breast Cancer Fund , earning $40,000. The report was filed on Oct. 16, 2009.
Original Filing: 300217738.xml
Lobbying Issues
Legislation in the 111th
HR1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation from the 110th
HR 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593)
The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill.
S 753, a bill to prohibit the manufacture, sale, or distribution in commerce of children's food and beverage containers composed of bisphenol A, and for other purposes. The Breast Cancer Fund has been meeting with staff to discuss how it relates to S. 593 and HR 1523.
House and Senate appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC.
Future Legislative Proposals
The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
Regulation and Legislative Intent
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetis legislation, and the FDAs transparency policies more generally.
P.L. 110-314 The Consumer Product Safety Commission Improvement Act
This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation.
P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008
This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2009
In Q2, The Raben Group lobbied for Breast Cancer Fund , earning $30,000. The report was filed on July 20, 2009.
Original Filing: 300189353.xml
Lobbying Issues
Legislation in the 111th
HR1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation from the 110th
HR 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593)
The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill.
S 753, a bill to prohibit the manufacture, sale, or distribution in commerce of children's food and beverage containers composed of bisphenol A, and for other purposes. The Breast Cancer Fund has been meeting with staff to discuss how it relates to S. 593 and HR 1523.
House and Senate appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC.
Future Legislative Proposals
The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
The Breast Cancer Fund has met with Congresswoman Slaughters office to propose revisions to a bill previously introduced in the 110th as HR 5809, the Environmental Hormone Disruption Act (no Senate version). This bill would authorize the director of the National Institute of Environmental Health Sciences (NIEHS) to establish a comprehensive program to better understand the impact of hormone disrupting pollutants in the environment on the health of women and children. The Breast Cancer Fund supports this legislation because of the need for more research on the links between environmental hazards and health.
The Breast Cancer Fund supports reform of the Toxic Substances Control Act. Senator Lautenberg is currently revising a version of his legislation from the 110th, S.3040 Kid-Safe Chemicals Act, and The Breast Cancer Fund has joined with other advocates to review draft language. The bill would amend the Toxic Substances Control Act to reduce the exposure of children, workers, and consumers to toxic chemical substances.
Regulation and Legislative Intent
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA and the FDAs transparency policies more generally.
P.L. 110-314 The Consumer Product Safety Commission Improvement Act
This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation.
P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008
This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2009
The Raben Group amended a lobbying report for representation of Breast Cancer Fund in Q12009 on June 10, 2010.
Original Filing: 300280270.xml
Lobbying Issues
Legislation in the 111th
HR1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation from the 110th
HR 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593)
The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill.
S 753, a bill to prohibit the manufacture, sale, or distribution in commerce of children's food and beverage containers composed of bisphenol A, and for other purposes. The Breast Cancer Fund has been meeting with staff to discuss how it relates to S. 593 and HR 1523.
House and Senate appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC.
Future Legislative Proposals
The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
The Breast Cancer Fund has met with Congresswoman Slaughters office to propose revisions to a bill previously introduced in the 110th as HR 5809, the Environmental Hormone Disruption Act (no Senate version). This bill would authorize the director of the National Institute of Environmental Health Sciences (NIEHS) to establish a comprehensive program to better understand the impact of hormone disrupting pollutants in the environment on the health of women and children. The Breast Cancer Fund supports this legislation because of the need for more research on the links between environmental hazards and health.
The Breast Cancer Fund supports reform of the Toxic Substances Control Act. Senator Lautenberg is currently revising a version of his legislation from the 110th, S.3040 Kid-Safe Chemicals Act, and The Breast Cancer Fund has joined with other advocates to review draft language. The bill would amend the Toxic Substances Control Act to reduce the exposure of children, workers, and consumers to toxic chemical substances.
Regulation and Legislative Intent
P.L. 110-314 The Consumer Product Safety Commission Improvement Act
This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation.
P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008
This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2009
In Q1, The Raben Group lobbied for Breast Cancer Fund , earning $30,000. The report was filed on April 19, 2009.
Original Filing: 300155880.xml
Lobbying Issues
Legislation in the 111th
HR1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593) Continued: Legislation from the 110th
HR 1523, the Ban Poisonous Additives Act of 2009 (Senate version S. 593)
The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill.
S 753, a bill to prohibit the manufacture, sale, or distribution in commerce of children's food and beverage containers composed of bisphenol A, and for other purposes. The Breast Cancer Fund has been meeting with staff to discuss how it relates to S. 593 and HR 1523.
House and Senate appropriations The Breast Cancer Fund has been speaking with House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC.
Future Legislative Proposals
The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
The Breast Cancer Fund has met with Congresswoman Slaughters office to propose revisions to a bill previously introduced in the 110th as HR 5809, the Environmental Hormone Disruption Act (no Senate version). This bill would authorize the director of the National Institute of Environmental Health Sciences (NIEHS) to establish a comprehensive program to better understand the impact of hormone disrupting pollutants in the environment on the health of women and children. The Breast Cancer Fund supports this legislation because of the need for more research on the links between environmental hazards and health.
The Breast Cancer Fund supports reform of the Toxic Substances Control Act. Senator Lautenberg is currently revising a version of his legislation from the 110th, S.3040 Kid-Safe Chemicals Act, and The Breast Cancer Fund has joined with other advocates to review draft language. The bill would amend the Toxic Substances Control Act to reduce the exposure of children, workers, and consumers to toxic chemical substances.
Regulation and Legislative Intent
P.L. 110-314 The Consumer Product Safety Commission Improvement Act
This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment in the Senate and in conference negotiations which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now monitoring implementation of this law: calling on the Executive Branch to nominate a new Chair for the agency and submitting public comments on various stages of implementation.
P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008
This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2008
In Q4, The Raben Group lobbied for Breast Cancer Fund , earning $30,000. The report was filed on Jan. 21, 2009.
Original Filing: 300133638.xml
Lobbying Issues
Legislation from the 110th
HR 6228, the Ban Poisonous Additives Act (no Senate version). This bill would ban the chemical bisphenal-A from all food and beverage containers. Continued: Legislation from the 110th
HR 6228, the Ban Poisonous Additives Act (no Senate version)
The Breast Cancer Fund supports this legislation because bisphenal-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to explore revisions to H.R. 6228 in anticipation of the introduction of similar legislation in the 111th Congress.
HR 5809, the Environmental Hormone Disruption Act (no Senate version)
This bill would authorize the director of the National Institute of Environmental Health Sciences (NIEHS) to establish a comprehensive program to better understand the impact of hormone disrupting pollutants in the environment on the health of women and children. The Breast Cancer Fund supports this legislation because of the need for more research on the links between environmental hazards and health. The Breast Cancer Fund has been meeting with staff of the principal author Congresswoman Slaughter to re-draft the bill in anticipation of the introduction of a version of the bill in the 111th Congress.
Future Legislative Proposals
The Breast Cancer Fund has met with staff from the Senate HELP Committee to discuss future legislation for a second War on Cancer. The Breast Cancer Fund has provided counsel on sections of the bill pertaining to cancer and the environment.
The Breast Cancer Fund has also met with staff from various House offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
Regulation and Legislative Intent
P.L. 110-314 The Consumer Product Safety Commission Improvement Act
This law has broadly reformed and modernized the Consumer Product Safety Commission. The Breast Cancer Fund lobbied in support of a Feinstein amendment, which inserts phthalates as a banned substance in the manufacture of childrens toys. We are now working with legislative conferees and their staff to insure effective regulatory implementation of the bill by the Consumer Product Safety Commission including submission of public comment and investigation of specific determinations by the CPSCs legislation counsel regarding specific sections of the law.
P.L. 110-354 -- Breast Cancer and Environmental Research Act of 2008
This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.
H.R.962 Preservation of Antibiotics for Medical Treatment Act
Sponsor: Rep Slaughter, Louise McIntosh
Title: To amend the Federal Food, Drug, and Cosmetic Act to preserve the effectiveness of medically important antibiotics used in the treatment of human and animal diseases.
H.R.6432 Animal Drug User Fee
Sponsor: Rep Pallone, Frank, Jr.
Title: To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the animal drug user fee program, and for other purposes.
H.R.6100 Kid-Safe Chemicals Act
Sponsor: Rep Solis, Hilda L.
Title: To amend the Toxic Substances Control Act to reduce the exposure of children, workers, and consumers to toxic chemical substances.
S.3040 Kid-Safe Chemicals Act
Sponsor: Sen Lautenberg, Frank R.
Title: A bill to amend the Toxic Substances Control Act to reduce the exposure of children, workers, and consumers to toxic chemical substances.
H.R.398 Healthy Places Act
Sponsor: Rep Solis, Hilda L.
Title: To require Federal agencies to support health impact assessments and take other actions to improve health and the environmental quality of communities, and for other purposes.
H.R.1103 Environmental Justice Act
Sponsor: Rep Solis, Hilda L.
Title: To codify Executive Order 12898, relating to environmental justice, to require the Administrator of the Environmental Protection Agency to fully implement the recommendations of the Inspector General of the Agency and the Comptroller General of the United States, and for other purposes.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2008
In Q3, The Raben Group lobbied for Breast Cancer Fund , earning $30,000. The report was filed on Oct. 20, 2008.
Original Filing: 300102987.xml
Lobbying Issues
H.R. 3643/S. 2082 - The Coordinated Environmental Public Health Network Act of 2007
This bill would create a coordinated national health tracking program to examine the links between Americans' health and their exposure to environmental contaminants. The Breast Cancer Fund is interested because this would help identify the environmental causes of breast cancer.S. 2275 and H.R. 4030 The Children's Chemical Risk Reduction Act
These bills would prohibit the manufacture, sale, or distribution in commerce of certain children's products and child care articles that contain phthalates. Phthalates are known to be linked with breast cancer development, so the Breast Cancer Fund is interested in eliminating them from consumer products.
S. 2045 and H.R. 4040 The Consumer Product Safety Commission Reform Act
These bills would broadly reform and modernize the Consumer Product Safety Commission. The Breast Cancer fund has lobbied in support of a Feinstein amendment, which inserts phthalates as a banned substance in the manufacture of childrens toys.
House Labor, HHS Appropriations bill for Biomonitoring and Health Tracking for Fiscal year 2009.
HR 6228, the Ban Poisonous Additives Act (no Senate version)
This bill would ban the chemical bisphenol-A from all food and beverage containers. The Breast Cancer Fund supports this legislation because bisphenal-A has been linked to increased rates of cancer, as well as other significant health problems.
HR 5809, the Environmental Hormone Disruption Act (no Senate version)
This bill would authorize the director of the National Institute of Environmental Health Sciences (NIEHS) to establish a comprehensive program to better understand the impact of hormone disrupting pollutants in the environment on the health of women and children. The Breast Cancer Fund supports this legislation because of the need for more research on the links between environmental hazards and health.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2008
The Raben Group amended a lobbying report for representation of Breast Cancer Fund in Q32008 on Oct. 20, 2008.
Original Filing: 300105296.xml
Lobbying Issues
H.R. 3643/S. 2082 - The Coordinated Environmental Public Health Network Act of 2007
This bill would create a coordinated national health tracking program to examine the links between Americans' health and their exposure to environmental contaminants. The Breast Cancer Fund is interested because this would help identify the environmental causes of breast cancer.S. 2275 and H.R. 4030 The Children's Chemical Risk Reduction Act
These bills would prohibit the manufacture, sale, or distribution in commerce of certain children's products and child care articles that contain phthalates. Phthalates are known to be linked with breast cancer development, so the Breast Cancer Fund is interested in eliminating them from consumer products.
S. 2045 and H.R. 4040 The Consumer Product Safety Commission Reform Act
These bills would broadly reform and modernize the Consumer Product Safety Commission. The Breast Cancer fund has lobbied in support of a Feinstein amendment, which inserts phthalates as a banned substance in the manufacture of childrens toys.
Consumer Product Safety Commission Met with Commissioner Moore and Commission staff to discuss implementation of S. 2045/H.R. 4040 the Consumer Product Safety Commission Reform Act.
House Labor, HHS Appropriations bill for Biomonitoring and Health Tracking for Fiscal year 2009.
HR 6228, the Ban Poisonous Additives Act (no Senate version)
This bill would ban the chemical bisphenol-A from all food and beverage containers. The Breast Cancer Fund supports this legislation because bisphenal-A has been linked to increased rates of cancer, as well as other significant health problems.
HR 5809, the Environmental Hormone Disruption Act (no Senate version)
This bill would authorize the director of the National Institute of Environmental Health Sciences (NIEHS) to establish a comprehensive program to better understand the impact of hormone disrupting pollutants in the environment on the health of women and children. The Breast Cancer Fund supports this legislation because of the need for more research on the links between environmental hazards and health.
Food and Drug Administration Provide public comment encouraging the FDA to restrict the use of bisphenol A (BPA) in food packaging.
H.R.962 Preservation of Antibiotics for Medical Treatment Act
Sponsor: Rep Slaughter, Louise McIntosh
Title: To amend the Federal Food, Drug, and Cosmetic Act to preserve the effectiveness of medically important antibiotics used in the treatment of human and animal diseases.
H.R.6432 Animal Drug User Fee
Sponsor: Rep Pallone, Frank, Jr.
Title: To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the animal drug user fee program, and for other purposes.
H.R.6100 Kid-Safe Chemicals Act
Sponsor: Rep Solis, Hilda L.
Title: To amend the Toxic Substances Control Act to reduce the exposure of children, workers, and consumers to toxic chemical substances.
S.3040 Kid-Safe Chemicals Act
Sponsor: Sen Lautenberg, Frank R.
Title: A bill to amend the Toxic Substances Control Act to reduce the exposure of children, workers, and consumers to toxic chemical substances.
H.R.398 Healthy Places Act
Sponsor: Rep Solis, Hilda L.
Title: To require Federal agencies to support health impact assessments and take other actions to improve health and the environmental quality of communities, and for other purposes.
H.R.1103 Environmental Justice Act
Sponsor: Rep Solis, Hilda L.
Title: To codify Executive Order 12898, relating to environmental justice, to require the Administrator of the Environmental Protection Agency to fully implement the recommendations of the Inspector General of the Agency and the Comptroller General of the United States, and for other purposes.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2008
In Q2, The Raben Group lobbied for Breast Cancer Fund , earning $30,000. The report was filed on July 21, 2008.
Original Filing: 300080586.xml
Lobbying Issues
H.R. 3643/S. 2082 - The Coordinated Environmental Public Health Network Act of 2007
This bill would create a coordinated national health tracking program to examine the links between Americans' health and their exposure to environmental contaminants. The Breast Cancer Fund is interested because this would help identify the environmental causes of breast cancer.S. 2275 and H.R. 4030 The Children's Chemical Risk Reduction Act
These bills would prohibit the manufacture, sale, or distribution in commerce of certain children's products and child care articles that contain phthalates. Phthalates are known to be linked with breast cancer development, so the Breast Cancer Fund is interested in eliminating them from consumer products.
S. 2045 and H.R. 4040 The Consumer Product Safety Commission Reform Act
These bills would broadly reform and modernize the Consumer Product Safety Commission. The Breast Cancer fund has lobbied in support of a Feinstein amendment, which inserts phthalates as a banned substance in the manufacture of childrens toys.
House Labor, HHS Appropriations bill for Biomonitoring and Health Tracking for Fiscal year 2009.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2008
In Q1, The Raben Group lobbied for Breast Cancer Fund , earning $30,000. The report was filed on April 21, 2008.
Original Filing: 300048644.xml
Lobbying Issues
H.R. 3643/S. 2082 - The Coordinated Environmental Public Health Network Act of 2007
This bill would create a coordinated national health tracking program to examine the links between Americans' health and their exposure to environmental contaminants. The Breast Cancer Fund is interested because this would help identify the environmental causes of breast cancer.S. 2275 and H.R. 4030 The Children's Chemical Risk Reduction Act
These bills would prohibit the manufacture, sale, or distribution in commerce of certain children's products and child care articles that contain phthalates. Phthalates are known to be linked with breast cancer development, so the Breast Cancer Fund is interested in eliminating them from consumer products.
S. 2045 and H.R. 4040 The Consumer Product Safety Commission Reform Act
These bills would broadly reform and modernize the Consumer Product Safety Commission. The Breast Cancer fund has lobbied in support of a Feinstein amendment, which inserts phthalates as a banned substance in the manufacture of childrens toys.
Agencies Lobbied
U.S. House of Representatives
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...